动物造模,前列腺癌转移 z-bio 2021-10-29 289

　　Prostate cancer is the most common form of cancer in men, and one in six people suffers from prostate cancer. Prostate cancer is the second most deadly cancer. Currently, incomplete animal models hinder the research of diseases, and current animal models of diseases cannot mimic the most deadly aspects of diseases, such as metastasis.

　　At present, scientists at the Cold Spring Harbor Laboratory (CSHL) have developed a new method that can quickly create better mouse models to evaluate treatments for metastatic prostate cancer. This discovery allows scientists to study the cause while testing new treatments. Simultaneously. The most widely used mouse model of prostate cancer rarely occurs tumor metastasis, and it is almost impossible to study the endpoint of cancer progression, that is, metastatic events. In the study published in the journal Cancer Discovery, the Cold Spring Harbor Laboratory team reported that they have developed a new mouse model of primary prostate cancer with tumor metastasis. In order to create

　　In the model RapidCaP, scientists insert gene mutations directly into the prostate and at the same time inject luminescent markers, so that they can monitor metastasis, tumor regression treatment and disease recurrence in real time. Studies have shown that PI3 kinase activity is not significantly present in metastatic tumor cells. In these deadly scattered tumor cells, Trotman and his colleagues were surprised to find that another oncogene, Myc, "takes over" the role of PI3.

　　A study by the team revealed the role of Myc gene in metastasis. They found that simply increasing the amount of Myc protein can promote prostate tumor metastasis. Treating animals with prostate cancer with the newly discovered drug JQ1 (which reduces the amount of Myc protein in the cells) can successfully reduce metastasis. This indicates that the Myc gene is necessary for the maintenance of tumor cells that have metastasized throughout the body. Using RapidCaP system, revealed the role of Myc gene in prostate cancer metastasis. Therefore, the new model is expected to provide a fast and accurate test system for the development of new methods for the treatment of prostate cancer.